Tempus AI Inc. (NASDAQ:TEM) saw its stock rise 3% on Friday morning following news of an expanded partnership with Gilead Sciences Inc. (NASDAQ:GILD) aimed at advancing Gilead's oncology pipeline.
The newly broadened, multi-year agreement extends Gilead's access to Tempus' AI-driven Lens platform at an enterprise-wide level. Under the arrangement, Gilead will gain access to expanded datasets spanning multiple indications as well as dedicated analytical services provided by Tempus.
Gilead has previously tapped Tempus' repository of de-identified multimodal data for oncology research and development efforts. Those prior uses have included trial design, indication selection, biomarker strategy, health outcomes analysis, and clinical real world evidence, according to the announcement.
With the expanded collaboration, Gilead will leverage Tempus' multimodal data library to produce insights intended to inform clinical decision making in cancer treatment. The scope of that work, as described by the companies, centers on generating AI-driven analyses from the combined data assets.
"By providing access to the Tempus multimodal data library, we are empowering the Gilead team to further fuel its R&D engine with AI-driven insights," said Ryan Fukushima, CEO of Tempus Data & Apps. "We are thrilled to expand this collaboration, offering the multimodal depth necessary to uncover critical biological insights."
Tempus AI is described as a technology company that applies artificial intelligence through its data and analytics platforms to advance precision medicine. The expanded agreement reaffirms Gilead's use of Tempus' de-identified multimodal datasets in oncology development work.
Context and market reaction
The market response to the announcement was modest but positive for Tempus, with shares increasing by 3% on the morning of the disclosure. The agreement formalizes broader access for Gilead to Tempus' Lens platform and adds analytical services alongside expanded data coverage.
What is not disclosed
The companies provided limited public detail on commercial terms. Beyond the characterization of the collaboration as multi-year, the announcement did not specify financial terms or other contractual conditions.